8-K: IR-Med Inc. Receives $171,468 Advance Payment from Israeli Innovation Authority for Diabetic Foot Ulcer Device Development

IR-Med Inc. has secured an advance payment of $171,468 from the Israeli Innovation Authority (IIA) to support the development of a device for assessing diabetic foot ulcers.

Summary

• IR-Med Inc. received an advance payment of NIS 644,551 (approximately $171,468) from the Israeli Innovation Authority (IIA) on April 6, 2025.
• This funding supports the development of a device for assessing diabetic foot ulcers before skin breakage in diabetic patients.
• The IIA awarded the company a total of NIS 4,603,938 (approximately $1,222,786), including a grant of 40% or NIS 1,841,575 (approximately $489,035).
• The IIA award will be distributed in tranches based on specific milestones and the progress of the product development between January 1, 2025, and December 31, 2025.
• The project's approval is subject to the Encouragement of Industrial Research and Development Law, 5744-1984, and the IIA's rules and guidelines.
• IR-Med is required to comply with regulatory and reporting obligations, including limitations on intellectual property and changes in ownership or control.
• The company is also obligated to pay royalties to the IIA for revenues generated from the approved project.

Sentiment

Score: 7

Explanation: The announcement is positive as it details a significant grant for the company's research and development efforts. However, there are obligations and potential risks associated with the grant, preventing a higher score.

Positives

• IR-Med Inc. has secured significant funding from the Israeli Innovation Authority.
• The funding will support the development of a potentially valuable medical device.
• The IIA's support validates the company's research and development efforts.
• The grant reduces the financial burden on IR-Med for this specific project.

Risks

• The company is subject to regulatory and reporting obligations related to the grant.
• Limitations on intellectual property and changes in ownership or control could impact the company's future operations.
• The company is obligated to pay royalties to the IIA for revenues generated from the project.
• Future tranches of the award are contingent on meeting specific milestones and project progress.

Future Outlook

The IIA award will be distributed in tranches based on specific milestones and the progress of the product development, from January 1, 2025 to December 31, 2025.

Industry Context

This announcement highlights the ongoing innovation in medical device technology, particularly in the area of diabetic care. Government support through organizations like the IIA plays a crucial role in fostering such innovation.

Stakeholder Impact

• Shareholders will likely view the funding positively.
• Employees involved in the project will benefit from the resources provided by the grant.
• Diabetic patients could potentially benefit from the developed device.

Next Steps

• IR-Med will continue developing the device for assessing diabetic foot ulcers.
• IR-Med will need to meet specific milestones to receive further tranches of the IIA award.
• IR-Med will comply with all applicable regulatory and reporting obligations.

Key Dates

Keywords

Israeli Innovation Authority, diabetic foot ulcers, funding, grant, medical device, IR-Med, IIA, research and development